Last reviewed · How we verify
NCT06736457
Study on Safety and Performance of AdvanCore Bone Void Filler
NA trial testing AdvanCore bone grafting in Bone Fractures in 190 participants. Currently enrolling.
1 October 2026
Quick facts
| Lead sponsor | Artur Salgado SA |
|---|---|
| Phase | NA |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 190 |
| Start date | 29 May 2025 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
| Sites | 4 locations across Portugal |
Drugs / interventions tested
- AdvanCore bone grafting
Conditions studied
- Bone Fractures — all drugs for Bone Fractures →
- Bone Defects — all drugs for Bone Defects →
- Bone Loss — all drugs for Bone Loss →
- Bone Graft — all drugs for Bone Graft →
Sponsor
Artur Salgado SA
Who can join
18 and older, any sex, with Bone Fractures or Bone Defects. Patients with the condition only — healthy volunteers not accepted.
What's being measured
Primary outcomes are the specific endpoints the trial is designed to prove or disprove.
-
Freedom of bone reintervention (safety)
Time frame: 6 months post-surgery
The primary safety endpoint is defined as freedom of bone reintervention due to AdvanCore usage at 6 months, analyzing the occurrence of (S)AEs related to the device usage and/ or AdvanCore procedure that may lead to subjects' reoperation. -
Successful osteointegration (performance)
Time frame: 6 months post-surgery
The primary performance endpoint will analyze the AdvanCore integration at 6 months of surgery. This process is defined as osteointegration, which refers to the direct structural and functional connection of the living bone with the surface of the implant. The implant osteointegration will be assessed by imaging techniques selected according to the current clinical practices of each site. In this
Sponsor's own description
The objective of this study is to evaluate the safety and performance of AdvanCore implantable bone graft through a 12-month follow-up period in a prospective, parallel-group design, non-controlled, open label, multi-center and real-world setting study. This study is intended to satisfy post-market clinical follow-up requirements of CE Mark in Europe.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06736457
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Bone Fractures
Currently open trials in the same condition.
- NCT06592378 — Opioid Management for Discharged Emergency Department Patients · NA · recruiting
- NCT07352501 — Effectiveness of Pulsed Electromagnetic Fields and Nutraceutical Supplementation in Women With Distal Radius Fracture · NA · active not recruiting
- NCT06612762 — Naringenin Supplementation in Bone Fracture Patients · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06736457 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Artur Salgado SA
- Last refreshed: 30 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06736457.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing